Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
In laboratory cell-line and mouse studies, a Stanford-engineered small molecule that forces two proteins (the lymphoma oncogene BCL6 and the enzyme CDK9) into physical proximity reprogrammed BCL6 to switch ON…
Primary source cited
Last reviewed
In the single-arm, phase 1/2 EPCORE NHL-1 trial, epcoritamab — a subcutaneously-injected bispecific antibody that physically brings a patient's own T-cells into contact with lymphoma cells — produced an objective…
Primary source cited
Last reviewed
In the MZL cohort of the single-arm, phase 2 TRANSCEND FL trial, lisocabtagene maraleucel -- a CD19-directed CAR T-cell therapy -- produced an intent-to-treat overall response rate of 84.4% and…
Primary source cited
Last reviewed
In laboratory cell-line and mouse studies, a Stanford-engineered small molecule that forces two proteins (the lymphoma oncogene BCL6 and the enzyme CDK9) into physical proximity reprogrammed BCL6 to switch ON…
Primary source cited
Last reviewed
In the single-arm, phase 1/2 EPCORE NHL-1 trial, epcoritamab — a subcutaneously-injected bispecific antibody that physically brings a patient's own T-cells into contact with lymphoma cells — produced an objective…
Primary source cited
Last reviewed
In the MZL cohort of the single-arm, phase 2 TRANSCEND FL trial, lisocabtagene maraleucel -- a CD19-directed CAR T-cell therapy -- produced an intent-to-treat overall response rate of 84.4% and…
Primary source cited
Last reviewed
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-Induced Cell Death (bioRxiv preprint). DOI 10.1101/2025.03.14.643404, PMID 40166243.
Eligibility varies — review trial criteria.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial (Journal of Clinical Oncology). DOI 10.1200/JCO.22.01725, PMID 36548927.
Applies to the exact indication stated.
TRANSCEND FL trial registry (marginal zone lymphoma cohort). NCT04245839.
Applies to the exact indication stated.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.